ADAM I-123

DB19213InvestigationalSmall molecule

ADAM I-123 is under investigation in clinical trial NCT01160263 (Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and Controls).

Mechanism: Pharmacologically active on Sodium-dependent serotonin transporter
Curator reviewed
Formula / weight: C₁₅H₁₇IN₂S · 380.28 g/mol (avg)
Also known as: Benzenemethanamine, 2-((2-amino-4-(iodo-123i)phenyl)thio)-n,n-dimethyl-
Code names: 123I-ADAM · ADAM I-123

Resolves to

Compound

UNII20LJC2LC2JCAS305352-16-3ChEMBLCHEMBL2314218

Structure

InChIKeyKPKLDBBNSFWOFA-KIWWSDKQSA-NSMILESCN(C)CC1=CC=CC=C1SC1=CC=C([123I])C=C1N

Targets

P31645SLC6A4

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with ADAM I-123, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account